Targeting CREB for Cancer Therapy: Friend or Foe

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|4|384-391

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.4, 2010-06, pp. : 384-391

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erythropoietin in Stroke Therapy: Friend or Foe

By  

Current Medicinal Chemistry, Vol. 22, Iss. 10, 2015-04 ,pp. : 1205-1213

Bentham Science Publishers

Access to resources Recommend Favorite

Growth Factor Therapy in Atherosclerotic Disease-Friend or Foe

By  

Current Pharmaceutical Design, Vol. 13, Iss. 17, 2007-06 ,pp. : 1803-1810

Bentham Science Publishers

Access to resources Recommend Favorite

TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy

By Chou Jian-Liang   Chen Lin-Yu   Lai Hung-Cheng   Chan Michael WY  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 11, 2010-11 ,pp. : 1213-1223

Informa Healthcare

Access to resources Recommend Favorite

Tungsten or Wolfram: Friend or Foe?

By  

Current Medicinal Chemistry, Vol. 25, Iss. 1, 2018-01 ,pp. : 65-74

Bentham Science Publishers

Access to resources Recommend Favorite

COX-2: Friend or Foe?

By  

Current Pharmaceutical Design, Vol. 13, Iss. 16, 2007-06 ,pp. : 1715-1721

Bentham Science Publishers

Access to resources Recommend Favorite